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Dissecting the mechanisms of inflammation continues to
be an important goal of modern biology. The expression
of many common diseases results from inappropriate acti-
vation of inflammation, making this an important target
for drug development. Inflammatory mechanisms are
highly redundant and tissue injury is mediated by many
mediators, acting in concert. Because of this, inhibiting an
established inflammatory response is extremely difficult.
It is particularly important to try to identify proximal
events in inflammation in order to develop inhibitors
which may be of clinical value. Progress in achieving this
goal has been made recently in experiments that have
taken advantage of the availability of ‘knockout’ mice
with targeted mutations of either the gene encoding the
antibody constant region (Fc) receptor or that encoding a
neurotransmitter receptor.
The development of knockout mice with deficiencies of
specific predetermined proteins offers a tool for exploring
hierarchical pathways of inflammation. Sometimes, the
study of such animals has confirmed what has previously
been discovered from in vitro experiments. Often,
however, investigators have been surprised by unexpected
results, which fall into two general categories. The first,
and most upsetting, of these categories is an absence of
phenotype resulting from the deficiency of what the
investigators dearly believed was the most important
protein in the body. Such a result may be due to an unex-
pected redundancy of mechanisms, the failure to use an
appropriate challenge to reveal a phenotype, or the biolog-
ical unimportance of the protein in mice. The second,
more immediately rewarding, category is the identification
of an unexpected phenotype which may lead to the devel-
opment of a new series of research questions.
Finding the relevant experimental challenge to reveal a
phenotype may be extremely difficult. Humans with
protein deficiencies are usually identified because the phe-
notype has been revealed by an appropriate environmental
challenge. A good example of this is the way that deficien-
cies in proteins of the membrane attack complex of com-
plement are associated with the development of neisserial
meningitis and septicaemia [1]. The sole role in humans of
the membrane attack complex of complement would
appear to be that of host defence against Neisseriae, bacteria
which can survive inside cells. The finding that humans
lacking one of the protein components of the membrane
attack complex are susceptible to neisserial infection is an
excellent natural experimental demonstration of the
requirement for extracellular lysis of these organisms by
complement in host defence. In the absence of these data
from humans, imagine an investigator faced with a mouse
with no complement membrane attack complex, no pheno-
type and no clues. It would be very smart indeed to choose
neisserial infection as the experimental challenge.
A valuable technique for triggering inflammation mediated
by the immune system is the use of immune complexes.
These consist of any combination of antibody with antigen.
The binding of antibody to antigen promotes the removal
of foreign antigens, the mounting of an adaptive immune
response and the development of specific immunological
memory. Immune complexes may also be an important
cause of pathological tissue injury. This occurs in two situa-
tions. The first of these is when antigen persists because it
is not cleared effectively following formation of immune
complexes. Important examples of this are when the
antigen is an autoantigen that cannot be removed from the
body, or when the immune response is ineffective in con-
trolling the infection and there is continuing production of
antigens from the persistent infectious agent. The second
circumstance in which immune complexes cause tissue
injury is when the physiological clearance mechanisms are
overwhelmed by formation of a large amount of immune
complexes. A good example of this is serum sickness, which
may follow injection of large amounts of poorly catabolized
foreign antigen, such as streptokinase used to promote
thrombolysis in the treatment of myocardial infarction [2].
Immune complexes contain two types of potential ligand
that may trigger inflammatory responses in tissues (Fig. 1).
The first is the Fc portion of the antibody, which may
interact with Fc receptors on leucocytes, triggering their
effector functions. Complement provides a further series
of ligands, which may be further divided into two sub-
types. The first are fixed to the complex and include C1q
and covalently bound C3b and C4b and their cleavage
products. These may stimulate inflammatory leucocytes
through ligation of cell surface receptors by pathways very
similar to those induced by ligation of Fc receptors. The
second group of complement ligands are not fixed to the
complexes and include the soluble anaphylatoxins, C3a
and C5a, and the membrane attack complex, C5b-9.
These augment the inflammatory response, in the case of
the anaphylatoxins by ligation of G-protein-coupled recep-
tors, and in the case of the membrane attack complex by
perturbation of cell membranes. From this body of data it
seemed probable that deficiency of complement or Fc
receptors, or both, would abolish the inflammatory
response mediated by immune complexes.
The inflammatory response known as the Arthus reaction
has been used widely as a model to explore the pathogene-
sis of inflammatory injury to tissues induced by immune
complexes. Early this century, Arthus described the local
inflammatory response that follows the injection of antigen
into the skin of sensitized animals [3]. This model can be
varied — for example, one variant is the reverse passive
Arthus reaction, in which antigen is injected intravenously
and antibody subcutaneously. A further twist on this model
is intrapulmonary immune complex formation, in which
antigen is injected intravenously and antibody is introduced
into the trachea; this results in formation of immune com-
plexes across the alveolar wall. Each of these model reac-
tions has recently been tested in knockout mice to explore
the relative roles of complement and Fc receptors in the
induction of inflammation.
In skin, a combination of new knock-out experiments [4,5]
and older data [6] show that the reverse passive Arthus
reaction is dependent on both Fc- and complement-
mediated pathways [4–6]. In the new experiments [5],
depletion of complement using cobra venom factor did not
significantly reduce the inflammatory response in wild-
type mice. But, in mutant mice lacking the Fc receptor
FcgRIII, the response was diminished to a variable degree
which correlated inversely with the level of haemolytic
complement expressed in individual animals [5]. Complete
abolition of the response was only seen in the FcgRIII
mutant animals following depletion of complement. These
findings may be seen as confirmation of experiments per-
formed using C5-deficient or complement-depleted mice,
which showed that, at low concentrations of antibody,com-
plement-dependent inflammatory pathways dominated,
whereas at high antibody concentrations, complement-
independent pathways were more apparent [6].
The results from studies of the reverse passive Arthus
reaction in the lung are broadly consistent with those in
the skin, though in this case complement depletion or C5
deficiency seems to block the inflammatory response
more effectively than it does in the skin [7]. The observa-
tion that C5 deficiency has some protective effect against
the Arthus reaction in the lung [7], as in the skin, implies a
role for the anaphylatoxin C5a and/or the membrane
attack complex in this inflammatory response. This has
now been confirmed by experiments using two further
mutant strains of mice, which have revealed an additional
layer of complexity of the mechanisms of inflammation. 
Intrapulmonary immune complex formation was explored
in mice with targeted deletions of the either the substance
P receptor (NK-1R) or C5a receptor gene [8]. The inflam-
matory response following intrapulmonary immune com-
plex formation was absent in both NK-1R–/– and C5aR–/–
mice. Which comes first in the inflammatory response,
C5a or substance P? Levels of substance P and tumour
necrosis factor-a (TNF-a) were elevated following
immune complex challenge in both the C5aR–/– and NK-
1R–/– mice. This observation was used to argue that that
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Figure 1
Immune complexes trigger inflammation by ligation of Fc, C3 or
anaphylatoxin (such as C5a) receptors on mast cells and leucocytes,
such as neutrophils. The release of mediators from mast cells causes
an increase in local vascular permeability, which facilitates the access
of plasma proteins to tissues and thereby amplifies inflammation.
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the response to substance P occurs before C5 activation,
but in the absence of data on C5a levels in the NK-1R–/–
mice this conclusion is, while plausible, somewhat specu-
lative. Whatever the hierarchy of the inflammatory
cascade, these results show an important additional facet
to the inflammatory response to immune complexes —
the involvement of substance P, a neurotransmitter that is
expressed by macrophages and mast cells, as well as C-
type nerve fibres.
What is the cell type responsible for triggering tissue
injury in response to immune complexes in the Arthus
reaction? Several lines of evidence support an important
role for mast cells. A strain of mice lacking mast cells,
because of a deficiency of stem cell factor, c-kit, showed a
markedly reduced, though not abolished, reverse passive
Arthus reaction [9]. These mice have now been reconsti-
tuted with mast cells derived from either wild-type
animals or mutants deficient in the Fc receptor g chain
(FcgRIII) [10]. The Arthus response was only restored to
normal in mice reconstituted with mast cells bearing
FcgRIII, showing that immune complexes in this model
trigger mast cells to release their mediators and cause
inflammation by ligation of FcgRIII.
Several conclusions may be drawn from the first results of
this latest phase of research on inflammation using knock-
out mice. First, the relative importance of different path-
ways of inflammation may vary according to the type of
immune complex and its site of formation. The induction
of inflammation is blocked, in some circumstances, by the
absence of Fc receptors, and in others by a deficiency of
complement or complement receptors. Second, the mast
cell has been shown to play a pivotal role in the Arthus reac-
tion, similar to the role this cell plays in anaphylactic reac-
tions triggered by ligation of mast-cell-bound immuno-
glubulin E. Third, the exciting finding that deficiency of a
neurotransmitter receptor blocks immune-complex-medi-
ated inflammation in the lung opens up a new avenue of
research into mechanisms of inflammation induced by anti-
bodies. Neuroimmunology is alive and well.
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